Nurix Therapeutics (NRIX) Other financing activities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Other financing activities data on file, last reported at $1.2 million in Q2 2026.

• On a quarterly basis, Other financing activities rose 20250.0% year-over-year to $1.2 million in Q2 2026; TTM through May 2026 was $3.6 million, a 230.09% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, up 4.55% from the prior year.
• Other financing activities for Q2 2026 stood at $1.2 million, up from $375000.0 in the prior quarter.
• Over the last five years, Other financing activities for NRIX reached as high as $2.3 million in Q3 2024 and fell as low as -$93.0 million in Q4 2022.
• Historically, Other financing activities has averaged -$6.0 million across 5 years, with a median of $644500.0 in 2024.
• Across the five-year window, Other financing activities sank 7874.87% in 2022 and soared 20250.0% in 2026, its largest moves.
• Year by year, Other financing activities stood at -$93.0 million in 2022, then soared by 102.34% to $2.2 million in 2023, then slumped by 167.74% to -$1.5 million in 2024, then jumped by 235.82% to $2.0 million in 2025, then tumbled by 39.01% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $1.2 million in Q2 2026, $375000.0 in Q1 2026, and $2.0 million in Q3 2025.